June 19, 2014
Swiss pharma giant Novartis AG has begun global regulatory filings for its ruxolitinib for the treatment of polycythemia vera (PV) based on data from a PIII study indicating the drug significantly improved disease control. Ruxolitinib “will be also filed for...read more